Patents Assigned to CSL Behring GmbH
  • Patent number: 9511123
    Abstract: The present invention relates to pharmaceutical preparations comprising Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders. The invention further relates to the combined use of a Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the treatment and prevention of bleeding disorders, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by co-administration of a sulfated glycosaminoglycan and a hyaluronidase.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: December 6, 2016
    Assignee: CSL Behring GmbH
    Inventors: Sabine Zollner, Hubert Metzner
  • Patent number: 9393289
    Abstract: The present invention relates to pharmaceutical preparations comprising one or more Factor VIII and a sulfated glycosaminoglycan for increasing the bioavailability of Factor VIII upon non-intravenous administration. The invention further relates to the combined use of Factor VIII and a sulfated glycosaminoglycan for the treatment and prevention of bleeding disorders, whereby the bioavailability of Factor VIII is increased, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by coadminstration of a sulfated glycosaminoglycan.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: July 19, 2016
    Assignee: CSL Behring GmbH
    Inventors: Hubert Metzner, Sabine Zollner
  • Patent number: 9352016
    Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: May 31, 2016
    Assignee: CSL Behring GmbH
    Inventors: Stefan Zeitler, Marc Nolte, Stefan Schulte, Gerhard Dickneite, Ingo Pragst
  • Patent number: 9290561
    Abstract: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: March 22, 2016
    Assignee: CSL Behring GmbH
    Inventors: Thomas Weimer, Stefan Schulte, Hubert Metzner, Ulrich Kronthaler, Holger Lind, Wiegand Lang
  • Patent number: 9249404
    Abstract: The present invention relates to modified cDNA sequences coding for human Factor X and their derivatives with improved stability and modified activation sequences, recombinant expression vectors containing such cDNA sequences, and host cells transformed with such recombinant expression vectors. The invention also relates to recombinant factor X polypeptides and derivatives which have biological activities of the unmodified wild type protein but with improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: February 2, 2016
    Assignee: CSL Behring GmbH
    Inventors: Stefan Schulte, Hans-Peter Hauser, Uwe Kalina, Thomas Weimer
  • Publication number: 20150366947
    Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of plasm
    Type: Application
    Filed: December 5, 2013
    Publication date: December 24, 2015
    Applicant: CSL Behring GmbH
    Inventors: Hung PHAM, Jeffrey Michael HEY, Darren NGUY
  • Patent number: 9095564
    Abstract: The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: August 4, 2015
    Assignee: CSL Behring GmbH
    Inventors: Gerhard Dickneite, Ingo Pragst, Henrique Lessa, Thorsten Haas, Stefan Zeitler
  • Publication number: 20150150911
    Abstract: The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction said plasma fraction comprising antithrombin III wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine protease per ml of the plasma fraction.
    Type: Application
    Filed: May 14, 2012
    Publication date: June 4, 2015
    Applicant: CSL Behring GMBH
    Inventors: Stefan Schulte, Uwe Kalina, Michael Moses, Annette Feussner
  • Publication number: 20150087592
    Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Applicant: CSL Behring GmbH
    Inventors: Stefan Schulte, Rolf Spirig, Sabine Zollner, Michael Moses, Wilfried Wormsbaecher, Hans-Arnold Stoehr
  • Patent number: 8962802
    Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: February 24, 2015
    Assignee: CSL Behring GmbH
    Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
  • Publication number: 20140356346
    Abstract: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
    Type: Application
    Filed: May 15, 2014
    Publication date: December 4, 2014
    Applicant: CSL Behring GmbH
    Inventors: Thomas WEIMER, Stefan SCHULTE, Ulrich KRONTHALER, Wiegand LANG, Uwe LIEBING, Wilfried WORMSBÄCHER
  • Patent number: 8877711
    Abstract: A method is described that improves the transport properties of albumin produced on an industrial scale, wherein the albumin is mixed, during the production process, with substances that saturate the binding points on the albumin. Furthermore, pasteurized and then octanoate-reduced human albumin and therapeutic uses of such albumin is described. Such albumin may be useful in detoxifying human plasma, e.g. for the intravenous treatment of acute or chronic liver diseases, and as a dialysate in extracorporeal liver dialysis.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: November 4, 2014
    Assignee: CSL Behring GmbH
    Inventors: Peter Kiessling, Dietrich Bosse, Johannes Zeiss, Gaston Diderrich
  • Publication number: 20140273096
    Abstract: The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.
    Type: Application
    Filed: April 9, 2014
    Publication date: September 18, 2014
    Applicant: CSL Behring GmbH
    Inventors: Stefan SCHULTE, Thomas WEIMER, Hubert METZNER
  • Patent number: 8828939
    Abstract: The present invention relates to modified cDNA sequences coding for vitamin K-dependent polypeptides, in particular human Factor VII, human Factor VIIa, human Factor IX and human protein C and their derivatives with improved stability and extended plasma half life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: September 9, 2014
    Assignee: CSL Behring GmbH
    Inventors: Thomas Weimer, Stefan Schulte, Kay Hofmann, Hans-Peter Hauser
  • Publication number: 20140248686
    Abstract: The present invention relates to the field of modified therapeutic polypeptides with increased in vivo recovery compared to their non-modified parent polypeptide. For example, the invention relates to fusions of therapeutic polypeptides with recovery enhancing polypeptides connected directly or optionally connected by a linker peptide.
    Type: Application
    Filed: March 27, 2014
    Publication date: September 4, 2014
    Applicant: CSL Behring GMBH
    Inventors: Thomas Weimer, Hubert Metzner, Stefan Schulte, Wiegand Lang, Wilfried Wormsbacher
  • Patent number: 8765915
    Abstract: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
    Type: Grant
    Filed: February 3, 2007
    Date of Patent: July 1, 2014
    Assignee: CSL Behring GmbH
    Inventors: Thomas Weimer, Stefan Schulte, Ulrich Kronthaler, Wiegand Lang, Uwe Liebing, Wilfried Wormsbächer
  • Patent number: 8754194
    Abstract: The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: June 17, 2014
    Assignee: CSL Behring GmbH
    Inventors: Stefan Schulte, Thomas Weimer, Hubert Metzner
  • Patent number: 8715672
    Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: May 6, 2014
    Assignee: CSL Behring GmbH
    Inventors: Bernhard Nieswandt, Thomas Renne
  • Publication number: 20140094591
    Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Applicant: CSL Behring GmbH
    Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch
  • Patent number: 8653245
    Abstract: This invention relates to protein separation and purification methods for both alpha-1-antitrypsin (AAT, also known as alpha-1 proteinase inhibitor, API, and A.sub.1-PI) and Apolipoprotein A-I (ApoA-1) from, for example, a fraction of human blood plasma. In certain embodiments, the invention provides methods for separating AAT from ApoA-1 at the initial stage of purification, so that the same starting material can be used as a source for both proteins. The methods further pertain to providing compositions of AAT and of ApoA-1 suitable for pharmaceutical use and are suitable for large-scale purification.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: February 18, 2014
    Assignee: CSL Behring GmbH
    Inventors: Nathan Brinkman, Douglas Bigler, Reinhard Bolli, Vreni Foertsch